Hernia Mesh Mass Tort Marketing Campaigns For Lawyers

On October 2, 2024, Becton, Dickinson, and Company (BD), the owner of Bard, announced that it has reached a settlement that is expected to resolve the majority of hernia mesh lawsuits brought against it in the MDL (multi-district litigation) and Rhode Island state court. While no settlement amount has been confirmed, there is speculation that payouts may range between $50,000 and $100,000 per plaintiff. 

The Covidien hernia mesh litigation advances steadily with nearly 1,500 lawsuits, as plaintiff attorneys depose key corporate representatives. Meanwhile, the Bard hernia mesh MDL faces a standstill, prompting one family to request remand to Arizona due to settlement delays and health concerns. Judge Sargus denied this motion, citing the ongoing stay on remand requests.

A new Florida plaintiff joined the Covidien MDL, alleging complications from a Parietex ProGrip mesh implant. Both MDLs continue to grow, with Covidien reaching 1,472 cases and Bard surpassing 24,000.

The hernia mesh litigation rose again in August, with Bard cases totaling 23,990 and the Covidien to 1,410. New cases are coming up, some involving implants that are over ten years old. The recent orders issued by the MDL suggest a worldwide settlement in the offing with a discovery stay and an opt-out provision. At the same time, there are failures in trials in Bard that total up to up to $4 with three consecutive losses.

The hernia mesh MDL saw significant developments with the court approving two key orders. Case Management Order No. 52 imposes a limited stay on all cases, allowing for smooth administration while respecting the terms of the Master Settlement Agreement. Case Management Order No. 53 outlines procedures for plaintiffs opting out of the settlement. These orders indicate a nearing settlement. The number of active cases surged from 22,896 in June to 23,641.

Rumors of confidential settlements continue, with some firms reportedly reaching deals with Bard. A new study in JAMA Surgery highlights issues with robotic hernia repair surgery, showing higher recurrence rates within 10 years. The Bard MDL saw 640 new cases in May, totaling 22,896 pending cases. The Covidien MDL also continues to grow, with new deadlines extending the process further.

Settlement talks are intensifying, with Bard likely picking off law firms one by one. The Bard MDL added 583 new cases in April, bringing the total to 22,256. Covidien MDL sees an extension of deadlines due to significant discovery deficiencies, pushing potential settlements further into the future.

The Bard hernia mesh MDL added 411 new cases, reaching 21,673 pending cases. The Covidien MDL continues with extended deadlines for corporate discovery and expert witness depositions. Settlement talks in the Bard MDL are ongoing, with mediation sessions scheduled for late March to facilitate a resolution.

Settlement negotiations are the focus, with mediation sessions set for March 25-26. The Bard MDL saw a decrease in new case filings, reflecting a slowdown. A jury in New Jersey ruled in favor of LifeCell in a Strattice mesh case, while Covidien was ordered to release unredacted complaint files, moving the litigation forward.

Mediation is scheduled for early March to push for a settlement. The Bryan case trial is canceled to focus on global settlement talks. The Bard MDL added nearly 100 new cases in January, totaling 21,169 pending cases. Covidien faces a new lawsuit over its hernia mesh products, adding to its legal challenges.

The Bard hernia mesh MDL saw an increase of nearly 600 new cases since October, totaling 20,973 pending cases. Plaintiffs’ attorneys push for more trials to pressure Bard into a settlement. Covidien faces a new lawsuit alleging defective hernia mesh, while Bard’s appeal in the Stinson case is denied, maintaining the $500,000 verdict.